<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03774706</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/184/18</org_study_id>
    <nct_id>NCT03774706</nct_id>
  </id_info>
  <brief_title>Sublingual Misoprostol With or Without Intravenous Tranexamic Acid During Hemorrhagic Cesarean Section</brief_title>
  <official_title>Role of Sublingual Misoprostol With or Without Intravenous Tranexamic Acid for Reducing Post-partum Hemorrhage During and After Hemorrhagic Cesarean Section: A Double-Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose to evaluates the effects of sublingual misoprostol with or without intravenous
      tranexamic acid (TA) on reducing post-partum hemorrhage during and after hemorrhagic cesarean
      section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different uterotonic agents administration, mainly oxytocin, has been routinely used to
      reduce the frequency of cesarean section (CS) -related hemorrhage; however, some studies
      reported that oxytocin use in the setting of CS may result in maternal adverse effects,
      including hypotension and tachycardia., Therefore, investigating other therapeutic agents
      with lower adverse effects and higher efficacy is needed. Recently, a number of studies
      reported a correlation between fibrinogen decrease and cesarean-related hemorrhage.
      Furthermore, extensive tissue injury increases fibrinolysis by shifting the hemostatic
      equilibrium and contributing to bleeding. Therefore, anti-fibrinolytic agents, such as
      tranexamic acid (TA), reduce the risk of death in bleeding trauma patients. On the other
      hand, it has been suggested that TA administration reduces blood loss and the incidence of
      postpartum hemorrhage (PPH) in females after vaginal or elective CS verse effects and higher
      efficacy is needed. Moreover, misoprostol is a prostaglandin E1 analog which has been
      introduced as a uterotonic agent for preventing PPH following CS. A recent study reported
      that oral or sublingual misoprostol is more effective than the placebo in reducing severe
      PPH, following CS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind placebo randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients develop postpartum hemorrhage</measure>
    <time_frame>6 hours post operative</time_frame>
    <description>calculation of number of patients develop postpartum hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood loss (ml)</measure>
    <time_frame>during the operation</time_frame>
    <description>calculation of the amount of blood loss in ml by gravimetric methods</description>
  </secondary_outcome>
  <other_outcome>
    <measure>postoperative blood loss (ml)</measure>
    <time_frame>6 hours post operative</time_frame>
    <description>calculation of the amount of blood loss in ml by gravimetric methods</description>
  </other_outcome>
  <other_outcome>
    <measure>number of patients need blood transfusion</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>calculation of number of patients need blood transfusion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Misoprostol with TA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol with placebo to TA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>two tablets misoprostol 400 Î¼g sublingual</description>
    <arm_group_label>Misoprostol with TA</arm_group_label>
    <arm_group_label>Misoprostol with placebo to TA</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline</description>
    <arm_group_label>Misoprostol with TA</arm_group_label>
    <other_name>active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to tranexamic acid</intervention_name>
    <description>placebo to tranexamic acid (110 ml saline)</description>
    <arm_group_label>Misoprostol with placebo to TA</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women who undergone elective cesarean section (C.S) and exposed to intraoperative
             bleeding about 500 ml diagnosed by visual analog estimation due to atonic uterus

          -  age between 18 and 45 years, gestational age of 37-40 weeks, singleton pregnancy, CS
             with inferior segment incision, and spinal anesthesia.

        Exclusion Criteria:

          -  having an underlying disease (heart, liver, kidney, pulmonary, etc.),

          -  eclampsia and severe preeclampsia

          -  allergy to TA (such as known allergy or thromboembolic event during pregnancy) and
             misoprostol

          -  coagulation disorders

          -  refuse or unable to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women who undergo elective cesarean section (C.S) and exposed to intraoperative bleeding about 500 ml diagnosed by visual analog estimation due to atonic uterus</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f sallam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f sallam</last_name>
    <phone>01022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aswan University</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany f sallam, md</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.ed.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla w Shady, md</last_name>
      <phone>1019240504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

